Mankind Pharma Acquires Bharat Serums in Major Pharmaceutical Sector Deal

Mankind Pharma announced on Thursday its decision to fully acquire Bharat Serums and Vaccines (BSV) from Advent International for approximately Rs 13,630 crore. This acquisition is a significant step for Mankind Pharma, positioning it as a leader in the Indian women's health and fertility drug market. The deal also provides access to high-entry barrier products in critical care, supported by established complex R&D technology platforms.

Representative image

Strategic Acquisition

The agreement with Advent International involves Mankind Pharma acquiring a 100% stake in BSV. This move is expected to enhance Mankind Pharma's portfolio significantly. BSV has over five decades of experience in biopharmaceuticals, developing recombinant and niche biologic products in-house. The company has a strong branded product portfolio in women's health, fertility, and critical care.

BSV's CEO and MD, Sanjiv Navangul, highlighted the acquisition's importance. He stated, "With a proven and established leadership in women's health and critical care... BSV team will add immense value to Mankind Pharma as we grow together, synergise our strengths and explore opportunities towards bringing healthcare closer to every home in India and across the world."

Leadership and Growth

Rajeev Juneja, Vice-Chairman and MD of Mankind Pharma, expressed optimism about the acquisition. He said, "BSV's acquisition represents a pivotal milestone in Mankind's journey, establishing us as the market leader in Indian women's health and fertility segment." He also noted the significant growth potential in the women's health and fertility sector globally.

Shweta Jalan, Managing Partner and Head of Advent India, shared her confidence in the future of the combined entity. She remarked, "With the building blocks in place, we are confident that Mankind Pharma and BSV's management team will continue the accelerated journey to build one of India's largest pharma companies."

Financial Performance

BSV reported revenues of Rs 1,723 crore for FY24, achieving a 20% year-on-year growth with adjusted EBITDA margins of 28%. This financial performance underscores BSV's robust market presence and growth trajectory.

Mankind Pharma is one of India's largest pharmaceutical companies focusing on the domestic market. It operates across various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and antidiabetic segments.

Juneja also welcomed BSV's employees into the Mankind family. He stated, "We are also delighted to welcome BSV's over 2,500 members to our Mankind family. Together, we look forward to achieving even greater milestones and making a positive impact on women's health worldwide."

This acquisition marks a significant milestone for Mankind Pharma as it continues to expand its footprint in the pharmaceutical sector. The combined strengths of both companies are expected to drive further growth and innovation in healthcare solutions.